Cargando…

Development of a dual energy CT based model to assess response to treatment in patients with high grade serous ovarian cancer: a pilot cohort study

BACKGROUND: In patients with cancer, the current gold standard for assessing response to treatment involves measuring cancer lesions on computed tomography (CT) imaging. The percentage change in size of specific lesions determines whether patients have had a complete/partial response or progressive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alizzi, Zena, Gogbashian, Andrew, Karteris, Emmanouil, Hall, Marcia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10268407/ https://www.ncbi.nlm.nih.gov/pubmed/37322564 http://dx.doi.org/10.1186/s40644-023-00579-2

Ejemplares similares

Identification of RAD51 foci in cancer-associated circulating cells of patients with high-grade serous ovarian cancer: association with treatment outcomes
por: Alizzi, Zena, et al.
Publicado: (2023)

Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status
por: Saravi, Sayeh, et al.
Publicado: (2021)

Description of a Retrospective Cohort of Epithelial Ovarian Cancer Patients with Brain Metastases: Evaluation of the Role of PARP Inhibitors in this Setting
por: Alizzi, Zena, et al.
Publicado: (2023)

Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro
por: ROGERS-BROADWAY, KARLY-RAI, et al.
Publicado: (2016)

Why the dual origins of high grade serous ovarian cancer matter
por: Colvin, Emily K., et al.
Publicado: (2020)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

In Silico Study to Predict the Structural and Functional Consequences of SNPs on Biomarkers of Ovarian Cancer (OC) and BPA Exposure-Associated OC
por: Zahra, Aeman, et al.
Publicado: (2022)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

Identification of Potential Bisphenol A (BPA) Exposure Biomarkers in Ovarian Cancer
por: Zahra, Aeman, et al.
Publicado: (2021)

CT features of low grade serous carcinoma of the ovary
por: Pannu, Harpreet K.
Publicado: (2015)

Targeting the Microenvironment in High Grade Serous Ovarian Cancer
por: Nwani, Nkechiyere G., et al.
Publicado: (2018)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Cell Origins of High-Grade Serous Ovarian Cancer
por: Kim, Jaeyeon, et al.
Publicado: (2018)

Proteome profiling of low grade serous ovarian cancer
por: zadeh fakhar, Haniyeh Bashi, et al.
Publicado: (2019)

High-grade serous ovarian cancer: the clone wars
por: Salomon-Perzyński, Aleksander, et al.
Publicado: (2017)

Molecular Management of High-Grade Serous Ovarian Carcinoma
por: Punzón-Jiménez, Paula, et al.
Publicado: (2022)

The peritoneal tumour microenvironment of high-grade serous ovarian cancer
por: Leinster, D Andrew, et al.
Publicado: (2012)

High-grade serous ovarian carcinoma organoids as models of chromosomal instability
por: Vias, Maria, et al.
Publicado: (2023)

Kinase Inhibitors and Ovarian Cancer
por: Katopodis, Periklis, et al.
Publicado: (2019)

First-Line Management of Advanced High-Grade Serous Ovarian Cancer
por: Mahmood, Reem D., et al.
Publicado: (2020)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Differential Regulation of Genes by the Glucogenic Hormone Asprosin in Ovarian Cancer
por: Kerslake, Rachel, et al.
Publicado: (2022)

Low-grade serous carcinoma with extensive osseous metaplasia arising from ovarian serous cystadenofibroma
por: Ribeiro e Ribeiro, Renan, et al.
Publicado: (2021)

Trends of low-grade serous ovarian carcinoma in the United States
por: Matsuo, Koji, et al.
Publicado: (2018)

High grade serous ovarian carcinomas originate in the fallopian tube
por: Labidi-Galy, S. Intidhar, et al.
Publicado: (2017)

Spatially resolved transcriptomics of high-grade serous ovarian carcinoma
por: Stur, Elaine, et al.
Publicado: (2022)

Principles of dormancy evident in high-grade serous ovarian cancer
por: Shepherd, Trevor G., et al.
Publicado: (2022)

Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers
por: Azzalini, Eros, et al.
Publicado: (2023)

Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer
por: Chowdhury, Shrabanti, et al.
Publicado: (2023)

Chlamydia trachomatis infection in primary fallopian tube and high-grade serous ovarian cancers: a pilot study
por: Laban, Mohamed, et al.
Publicado: (2019)

Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer
por: Hillman, R Tyler, et al.
Publicado: (2017)

Transcriptional Landscape of 3D vs. 2D Ovarian Cancer Cell Models
por: Kerslake, Rachel, et al.
Publicado: (2023)

The Challenges of Clinical Research in Rare Cancers: Bevacizumab Use in Low-Grade Serous Ovarian and Primary Peritoneal Cancers
por: Grande, Carolyn, et al.
Publicado: (2017)

A pancancer overview of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer
por: Kerslake, Rachel, et al.
Publicado: (2021)

Elevated Circulating Lactate Levels and Widespread Expression of Its Cognate Receptor, Hydroxycarboxylic Acid Receptor 1 (HCAR1), in Ovarian Cancer
por: Kerslake, Rachel, et al.
Publicado: (2022)

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma
por: Norris, Eric J, et al.
Publicado: (2019)

Integration of proteomics with CT-based qualitative and radiomic features in high-grade serous ovarian cancer patients: an exploratory analysis
por: Beer, Lucian, et al.
Publicado: (2020)

Preoperative CT-based deep learning model for predicting overall survival in patients with high-grade serous ovarian cancer
por: Zheng, Yawen, et al.
Publicado: (2022)

Detection of Abundant Non-Haematopoietic Circulating Cancer-Related Cells in Patients with Advanced Epithelial Ovarian Cancer
por: Kumar, Juhi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hh0dj4bjcm67e0396opbnj3n0o